Cambridge Heart - HearTwave II

	Cambridge Heart Announces Changes to the Board of Directors
	Cambridge Heart Raises $1.8 Million in Private Placement
	Study Supports Use of MTWA Test as Predictor of Sudden Cardiac Death
	Cardiac Science and Cambridge Heart Announce Development Partnership
	Cambridge Heart Announces New Research and Development Initiative
	Cambridge Heart's Non-Invasive MTWA Test Accurately Predicts Risk of Sudden Cardiac Arrest

HearTwave® II Microvolt T-Wave Alternans™ System

The HearTwave II system is the next generation Microvolt T-Wave Alternans (MTWA) testing platform simplifying hospital and office-based SCD risk stratification while eliminating the need for a host stress system.

MTWA signal processing/analysis with proprietary Analytic Spectral Method®
Customized patient report generated by Alternans Report Classifier
Dedicated MTWA Graphic User Interface
Windows® XP operating system powered by Intel® Pentium® processor
Real time ECG monitoring built into the proprietary MTWA software
Large adjustable 15" color LCD display
Printer options include laser with Bluetooth or thermal
3000 test storage capacity before archiving to CD-RW, memory key or network
Test editing in real-time or in review mode
Compatible with most treadmills
Optional Stress Kit upgrade includes software and lead set to make the HearTwave II stress enabled

Safety and Performance Standards
In compliance with	CAN/CSA 22.2, EN60601-1, EN60601-1-1, EN60601-1-2. Meets the American National Standards for Diagnostic Electrocardiographic Devices (ANSI/AAMI EC-11, EC-12, EC-13, EC-53).
Chassis leakage	< 100 microamps
Patient leakage	< 10 microamps (isolated patient module with Type CF isolation barrier)
Physical and Environmental Specifications
Size	30" x 52 " x 20 "
Shipping weight	240 lbs
Power Requirements	100-240 V (±10%; 50/60 Hz)
Power Consumption	600 VA (max.)
Operating temperature	+10°C to 32.5°C (50°F to 91°F)
Humidity	30% to 80% non-condensing